Lianyungang Runzhong Pharmaceutical is an API manufacturer based in China. It holds 8 active US drug master files across a filed portfolio of 9 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 26 January 2024 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3003015655 |
| Molecule | Regulators | Docs |
|---|---|---|
| Fulvestrant | SFDA (Saudi Arabia), US FDA | 2 |
| Palbociclib | SFDA (Saudi Arabia), US FDA | 2 |
| Amifostine | US FDA | 1 |
| Budesonide | SFDA (Saudi Arabia) | 1 |
| Carfilzomib | US FDA | 1 |
| Degarelix | US FDA | 1 |
| Eribulin | US FDA | 1 |
| Fosaprepitant | US FDA | 1 |
| Foscarnet | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Lianyungang Runzhong Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free